The goal of the Career Development Program of the Northwestern University-University of Chicago SPORE in Prostate Cancer is to recruit talented investigators to a career in translational prostate cancer research. In the current project period the SPORE Career Development Program (CDA) funded 7 CDA investigators from a pool of 20 applicants. These investigators were successful in obtaining 14 grant awards and they published 66 papers related to their CDA projects. The fact that the faculty come from a variety of departments has provided a source of diversity and scientific expertise to the investigators in the Program. Special efforts have been placed to emphasize the recruitment of women and minorities to the SPORE CDA. The Career Development Program has demonstrated flexibility in terms of offering awards and the length of the award. In the current funding period, the Prostate SPORE has maintained a consistent and highly structured process for advertisement of CDA positions, selection of CDA investigators and a good tracking system for monitoring and evaluating their progress. In the last SPORE submission, the CDA received an assessment of """"""""Excellent"""""""". In this revised application, we have updated information of all CDA investigators and we again propose CDA funding for two investigators, one is to a woman (Hou) and the other is to a minority applicant (Posadas

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090386-06A2
Application #
7587137
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Project Start
2008-10-01
Project End
2013-09-30
Budget Start
2008-10-01
Budget End
2010-01-31
Support Year
6
Fiscal Year
2009
Total Cost
$61,375
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Hung, Michelle E; Lenzini, Stephen B; Stranford, Devin M et al. (2018) Enrichment of Extracellular Vesicle Subpopulations Via Affinity Chromatography. Methods Mol Biol 1740:109-124
Weiner, Adam B; Tsai, Kyle P; Keeter, Mary-Kate et al. (2018) The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. J Urol 200:1048-1055
Nettey, Oluwarotimi S; Walker, Austin J; Keeter, Mary Kate et al. (2018) Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. Urol Oncol 36:501.e1-501.e8
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Zhang, Qiang; Helfand, Brian T; Carneiro, Benedito A et al. (2018) Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol 73:648-652
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Dominguez, Donye; Ye, Cong; Geng, Zhe et al. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol 198:1365-1375
Murphy, A B; Nyame, Y A; Batai, K et al. (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55-60
Loeb, Stacy; Shin, Sanghyuk S; Broyles, Dennis L et al. (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120:61-68
Zhang, Minghui; Dominguez, Donye; Chen, Siqi et al. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett 14:3580-3586

Showing the most recent 10 out of 209 publications